Literature DB >> 2673623

Determination and comparison of the pressor effect of tyramine during long-term moclobemide and tranylcypromine treatment in healthy volunteers.

I Berlin1, R Zimmer, A Cournot, C Payan, A M Pedarriosse, A J Puech.   

Abstract

Monoamine oxidase inhibitors can elicit increases in systolic blood pressure after tyramine ingestion (cheese effect). Moclobemide is a new, reversible, preferential monoamine oxidase A inhibitor with antidepressant properties. Its potentiation of the tyramine pressor effect during 200 mg t.i.d. chronic treatment was compared with tranylcypromine, 10 mg b.i.d., in a double-blind, parallel-group, placebo-controlled study (n = 16). Tyramine was mixed with food and ingested in increasing daily doses, during a normal meal, until a systolic blood pressure increase of at least 30 mm Hg was achieved (tyramine 30). When compared with the usual fasting oral tyramine tests performed in the same subjects, the mean tyramine 30 dose with a meal was 2.8 times higher. The mean tyramine 30 dose with a meal decreased from 1450 mg (range, 800 to 2000 mg) during placebo to 306 mg (range, 150 to 500 mg) during moclobemide (factor, 5.0) and from 1200 mg (range, 1000 to 1600 mg) during placebo to 35 mg (range, 20 to 50 mg) during tranylcypromine (factor, 38.2). The duration of the systolic blood pressure increase was longer with tranylcypromine (126 minutes) than with moclobemide (69 minutes) (p less than 0.01).

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2673623     DOI: 10.1038/clpt.1989.149

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  11 in total

Review 1.  Clinically significant drug interactions with antidepressants in the elderly.

Authors:  Edoardo Spina; Maria Gabriella Scordo
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

2.  The effects of moclobemide on the pharmacokinetics of the 5-HT1B/1D agonist rizatriptan in healthy volunteers.

Authors:  A D Van Haarst; J M Van Gerven; A F Cohen; M De Smet; A Sterrett; K L Birk; A L Fisher; M E De Puy; M R Goldberg; D G Musson
Journal:  Br J Clin Pharmacol       Date:  1999-08       Impact factor: 4.335

3.  Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects.

Authors:  I Berlin; R Zimmer; H M Thiede; C Payan; T Hergueta; L Robin; A J Puech
Journal:  Br J Clin Pharmacol       Date:  1990-12       Impact factor: 4.335

Review 4.  The Prescriber's Guide to the MAOI Diet-Thinking Through Tyramine Troubles.

Authors:  Vincent Van den Eynde; Peter Kenneth Gillman; Barry B Blackwell
Journal:  Psychopharmacol Bull       Date:  2022-05-31

5.  Evaluation and comparison of the interaction between alcohol and moclobemide or clomipramine in healthy subjects.

Authors:  I Berlin; A Cournot; R Zimmer; A M Pedarriosse; R Manfredi; P Molinier; A J Puech
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

6.  The trace amine theory of spontaneous hypertension as induced by classic monoamine oxidase inhibitors.

Authors:  Vincent Van den Eynde
Journal:  J Neural Transm (Vienna)       Date:  2021-08-09       Impact factor: 3.575

Review 7.  Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide.

Authors:  M Mayersohn; T W Guentert
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

8.  Influence of food on the tyramine pressor effect during chronic moclobemide treatment of healthy volunteers.

Authors:  C Audebert; O Blin; S Monjanel-Mouterde; P Auquier; A M Pedarriosse; J Dingemanse; A Durand; J P Cano
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 9.  A reassessment of the safety profile of monoamine oxidase inhibitors: elucidating tired old tyramine myths.

Authors:  Peter Kenneth Gillman
Journal:  J Neural Transm (Vienna)       Date:  2018-09-25       Impact factor: 3.575

Review 10.  Comparative tolerability profiles of the newer versus older antidepressants.

Authors:  M V Rudorfer; H K Manji; W Z Potter
Journal:  Drug Saf       Date:  1994-01       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.